Value assessment is a hot topic in healthcare. But how can it be improved so it's more relevant to answering the most important questions to patients, payers and providers? In this commentary, Jennifer Bright explains why we need data partners to catalyze improvement in value assessment. Read the article here.
Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done the right way; and Momentum to improve value assessment models. Read the full article here. Please note that a Scrip [...]
Jennifer Bright writes in Morning Consult that while we've made progress assessing the value of biopharmaceuticals, more focus is needed to develop bout transparent, patient-centered value assessment methods in healthcare technologies beyond drugs. Read the full article here.
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are getting the most value out of their consultants' recommendations. Read the full article here.
After the release of the public comments for IVI-NSCLC, Managed Healthcare Executive took a look at IVI's open-source model focusing on non-small lung cancer and how it will bring healthcare executives insight into value that otherwise wouldn't exist with traditional models. Read the full article here.
In the wake of this year's ISPOR conference, IVI's Executive Director, Jennifer Bright, reflects on how to move value assessment from a static snapshot in time to an active learning approach. She discusses the following five steps to improving value assessment: Take the transparency challenge. Embrace flexibility. Allow for iteration. Improve incorporation of non-clinical data. [...]
IVI Executive Director, Jennifer Bright, writes in Morning Consult about the differences between patient-centered and consumer-driven healthcare. Read the full article here.
In a Morning Consult commentary, IVI Executive Director, Jennifer Bright, discusses why transparency is a prerequisite to value-based reimbursement and how IVI's Open-Source Value Platform (OSVP) is an open laboratory for creating sophisticated systems to assess value in healthcare. Read the full article here.
In an article published online by the American Journal of Managed Care, IVI's Executive Director, Jennifer Bright, and Director of Scientific Communications, Mark Linthicum, offer five predictions for where value assessment is headed in 2019. Specifically, Jennifer and Mark focus their discussion on the following areas of interest regarding value assessment: Including patient perspectives becomes [...]